Loading...

457 posters, 2 videos, 2 audios, 8 topics, 45 sessions, 401 authors, 265 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

49th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

March 21-23, 2024 | The Hilton Bayfront San Diego | San Diego, California

49th Annual Regional Anesthesiology and Acute Pain Medicine Meeting banner

5275

RETROSPECTIVE REVIEW OF PUDENDAL NEURALGIA TREATED WITH PULSED RADIOFREQUENCY ABLATIONS

Poster Presenter

Monika Schmitt

Part of Topic

Scientific Abstracts > Chronic Pain

Retrospective Review of Pudendal Neuralgia Treated With Pulsed Radiofrequency Ablations 

●Pudendal neuralgia (PN), a debilitating pain condition primarily localized to the genital and rectal areas, affects 1 in 100,000 people. [1]
●Cases reported in the literature are often initially misdiagnosed given this syndrome’s complex symptomatology. [2]
●Common treatment modalities include behavioral modifications, physical therapy, pharmacological agents, and botulinum toxin A injections. However, if these treatments fail, pudendal nerve injection can be an effective option. [3]
●When pudendal nerve injections are effective but only provide temporary relief, pulsed radiofrequency ablation (PRF) of the pudendal nerve is a potential treatment that could provide longer lasting relief. Through increasingly understood mechanisms, PRF neurolysis has been shown to treat chronic pain conditions such as trigeminal neuralgia, chronic low back pain, postherpetic neuralgia, and complex regional pain syndrome to name a few. [4] We hope to further advance the application of PRF to patients with PN and its efficacy after pudendal nerve blockade.

This is an IRB-approved five-year retrospective review of patients who received significant pain relief lasting <2 weeks from fluoroscopy-guided transgluteal pudendal nerve block and then underwent PRF of the pudendal nerve. Position of PRF cannula was confirmed with fluoroscopy (Figure 1).

Radiofrequency cannula positioned near the ischial spine tip in the ipsilateral oblique fluoroscopic view on left side. Contrast administered at site to ensure cannula not in a vessel. FH: femoral head. IS: ischial spine. IL: ilium.

Eight patients had fewer than two weeks of pain relief with pudendal nerve block and went on to PRF, which was the criteria for enrollment (Table 1). Out of those that underwent PRF, four had >75% of pain relief that lasted for an average of 80 days. Two had at least 25% of pain relief for an average of at least 30 days. Two had no relief. Six out of the eight patients were female. All patients had pain that was not amenable to prior treatments such as pharmacotherapy and pelvic floor physical therapy.

PRF uses radio waves to destroy abnormal or dysfunctional tissue with increasing utility in treating chronic pain. [5] Multiple hypotheses exist. However, it is thought that PRF produces prolonged analgesia by inhibiting excitatory C-fibers. [4] Analysis of this retrospective review suggests that PRF of the pudendal nerve with the use of fluoroscopy could become a more commonplace treatment of PN. Advantages of PRF include long-lasting pain relief, creation of precise and accurate lesions, and safeguarding against ablating unintended targets prior to lesioning due to the ability to stimulate nervous system elements. [6] Although rare, complications of PRF include thermal burns, bleeding, infection, and inadvertent nerve damage. [7] This review exemplifies, in conjunction with previous studies, that transgluteal PRF for PN to be an effective, minimally invasive option after the failure of conservative management. [8] Most of the patients in our review experienced pain control for longer durations previously obtained from nerve blockade. Additional studies are needed to determine the exact mechanisms of PRF and its utility in an increasing number of chronic pain conditions. 

 

49th Annual Regional Anesthesiology and Acute Pain Medicine Meeting » banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.